NETs are rare, heterogeneous group of neoplasm
presented as chronic oncologic disease. Somatostatin analogue is the standard
first line systemic therapy for mainly hormone control.
No standard second line systemic treatment is
available except everolimus which has no reported complete response. PRRT is an
innovative molecular targeted
treatment based on theragnostic concept for well differentiated NETs.
We presented here a 63-year-old lady with
grade 1 NET of rectum with lymphnodal and liver metastasis. She underwent
sigmoid colostomy for bowel symptoms and started on sandostatin LAR.
No comments:
Post a Comment